By Josh White
Date: Thursday 09 Apr 2026
(Sharecast News) - Avacta Therapeutics said on Thursday that it had made "important milestones" in the first quarter of 2026, as the clinical-stage oncology company advanced its preCISION platform and secured additional funding to support development through key data readouts later this year.
By Josh White
Date: Tuesday 24 Feb 2026
(Sharecast News) - Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages over the marketed antibody drug conjugate Enhertu, as it prepared to begin a phase one trial of its lead programme AVA6103 in the first quarter of 2026.
By Josh White
Date: Monday 09 Feb 2026
(Sharecast News) - Avacta Therapeutics announced the appointment of Francis Wilson as its chief scientific officer on Monday, effective immediately, as the AIM-traded clinical-stage biopharmaceutical company prepared for further development of its 'preCISION' tumour-activated oncology delivery platform.
| Currency | UK Pounds |
| Share Price | 70.50p |
| Change Today | 0.50p |
| % Change | 0.71 % |
| 52 Week High | 82.50p |
| 52 Week Low | 27.50p |
| Volume | 659,249 |
| Shares Issued | 456.29m |
| Market Cap | £321.68m |
| Beta | 0.01 |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 11:48 | 5,000 @ 69.22p |
| 11:45 | 200 @ 69.22p |
| 11:44 | 12,301 @ 69.22p |
| 11:43 | 1,458 @ 69.13p |
| 11:30 | 7,162 @ 69.75p |
You are here: research